Possible dopaminergic stimulation of locus coeruleus alpha1-adrenoceptors involved in behavioral activation.
alpha(1)-Adrenoceptors of the locus coeruleus (LC) have been implicated in behavioral activation in novel surroundings, but the endogenous agonist that activates these receptors has not been established. In addition to the canonical activation of alpha(1)-receptors by norepinephrine (NE), there is evidence that dopamine (DA) may also activate certain brain alpha(1)-receptors. This study examined the contribution of DA to exploratory activity in a novel cage by determining the effect of infusion of various dopaminergic and adrenergic drugs into the mouse LC. It was found that the D2/D3 agonist, quinpirole, which selectively blocks the release of CNS DA, produced a dose-dependent and virtually complete abolition of exploration and all movement in the novel cage test. The quinpirole-induced inactivity was significantly attenuated by coinfusion of DA but not by the D1 agonist, SKF38390. Furthermore, the DA attenuation of quinpirole inactivity was blocked by coinfusion of the alpha(1)-adrenergic receptor antagonist, terazosin, but not by the D1 receptor antagonist, SCH23390. LC infusions of either quinpirole or terazosin also produced profound inactivity in DA-beta-hydroxylase knockout (Dbh -/-) mice that lack NE, indicating that their behavioral effects were not due to an alteration of the release or action of LC NE. Measurement of endogenous DA, NE, and 5HT and their metabolites in the LC during exposure to the novel cage indicated an increase in the turnover of DA and NE but not 5HT. These results indicate that DA is a candidate as an endogenous agonist for behaviorally activating LC alpha(1)-receptors and may play a role in the activation of this nucleus by novel surroundings.
Lin
Yan
Y
Department of Psychiatry, New York University School of Medicine, New York, New York 10016, USA.
Quartermain
David
D
Dunn
Adrian J
AJ
Weinshenker
David
D
Stone
Eric A
EA
D058646:Adrenergic alpha-1 Receptor Agonists; D000818:Animals; D001143:Arousal / Q000187:drug effects / Q000502:physiology*; D004298:Dopamine / Q000378:metabolism*; D018491:Dopamine Agonists / Q000494:pharmacology; D018492:Dopamine Antagonists / Q000494:pharmacology; D004299:Dopamine beta-Hydroxylase / Q000235:genetics; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions / Q000502:physiology; D005106:Exploratory Behavior / Q000187:drug effects / Q000502:physiology*; D005260:Female; D008125:Locus Coeruleus / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D009638:Norepinephrine / Q000096:biosynthesis; D018340:Receptors, Adrenergic, alpha-1 / Q000378:metabolism*; D012701:Serotonin / Q000378:metabolism; D009435:Synaptic Transmission / Q000187:drug effects / Q000502:physiology*
D058646:Adrenergic alpha-1 Receptor Agonists; D018491:Dopamine Agonists; D018492:Dopamine Antagonists; D018340:Receptors, Adrenergic, alpha-1; D012701:Serotonin; D004299:Dopamine beta-Hydroxylase; D004298:Dopamine; D009638:Norepinephrine